Tryptophan (W) is an essential amino acid which is primarily required for protein synthesis. It also acts as 5 a precursor of key biomolecules for human health (serotonin, melatonin, tryptamine, niacin, nicotinamide adenine dinucleotide (NAD), phosphorylated NAD (NADP), quinolinic acid, kynureric acid, etc.). Among dietary proteins, milk proteins are particularly rich in W. W residues within milk proteins may be released by proteolytic/peptidolytic enzymes either as a free amino acid or as part of peptide sequences. Different W-containing peptides originating from milk proteins have been shown in vitro to display a 10 wide range of bioactivities such as angiotensin converting enzyme (ACE) inhibition along with antioxidant, antidiabetic and satiating related properties. Free W has been shown in certain instances to have an effect on cognition and the aforementioned bioactive properties. However, a higher bioactive potency has generally been observed with specific W-containing peptides compared to free W. Since W is thermolabile, the impact of processing on the stability of W-containing peptides needs to be considered.
Introduction
The name "tryptophan" (W, molecular formula: C 11 H 12 N 2 O 2 , molecular mass: 204.23 Da) originates from the time when this 20 amino acid was first isolated from a casein (CN) tryptic digest by Hopkins and Cole 1 . Of the twenty conventional amino acids, W is the only one which possesses an indole structure. W is classified within the category of hydrophobic amino acids. It is formed through the condensation of serine (S) with an indole 25 group. This reaction is catalysed by W synthase in lower organisms, including microorganisms. As an essential amino acid, it cannot be synthesised by humans and animals because they are lacking in W synthase. Therefore, W has to be supplied to the body by exogenous sources, notably through the diet 2, 3 . A 30 requirement of 4 mg kg -1 day -1 for adults has been set by the WHO for healthy metabolism 4 . W has been reported to be the amino acid with the lowest concentration within the human body 5, 6 . W deficiencies can have several consequences for human health including the onset of diseases such as pellagra (caused by 35 niacin deficiency), as well as psychological, cognitive and behavioral disorders such as dementia and depression 5, 6 . In the human body, the primary function of W is protein synthesis, with the L isomer being the only one which can be incorporated in proteins 5, 6 . W is also a precursor for the synthesis 40 of serotonin, melatonin, tryptamine, niacin, nicotinamide adenine dinucleotide (NAD), NAD phosphorylated (NADP), quinolinic acid and kynureric acid ( Fig. 1 ) 2, 5, 6 . Kynurenine acts as a precursor of kynurenic and quinolinic acid which are antagonists and agonists of the glutamate receptor, respectively. Kynurenine 45 has also been shown to retard cataract formation due to its role as a UV filter in the retina 5 . W is the sole precursor of serotonin, which has been reported to have an effect on psychological status and satiety in humans. This effect may be modulated by tryptamine, which results from the decarboxylation of W 5 . A link 50 between W and the immune response has also been suggested. It is thought that W breakdown can reduce T cell proliferation on the one hand. On the other hand, the metabolites generated within the kynurenine pathway (taking place in the immune system) can modulate various inflammatory responses 2 .
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W is found within a wide range of dietary proteins (See USDA National Nutrient Database for W 7 ). However, certain protein sources are richer in W than others. Several dietary proteins have been described as good sources of W (> 0.3% (w/w)), these include egg, soy, bean, seafood, poultry and milk proteins 7 . The 60 major milk proteins contain between 1 (-and -CN) and 13 (lactoferrin -LF, Table 1 ) W residues per molecule. In general, whey proteins possess more W residues than CNs. In particular, -lactalbumin (-La), which possesses 4 W residues per molecule, shows the highest W content (5.3% (w/w); Table 1 ) of 65 milk proteins. Following milk protein digestion, free amino acids and peptides are released in the gastrointestinal tract (GIT). These free amino acids and peptides may have different beneficial effects as health promoting agents 8 . Numerous studies have 70 shown that milk proteins comprise specific peptide sequences, known as bioactive peptides (BAPs), which are able to modulate different key health biomarkers 9, 10 . Various antihypertensive, antioxidant, mineral binding, antimicrobial and anticancer activities have been demonstrated in vitro [11] [12] [13] [14] [15] . A number of 75 human intervention studies have concluded in positive health outcomes following the consumption of dairy products and milk protein-derived BAPs [16] [17] [18] [19] [20] [21] [22] [23] [24] . The detection of peptides within complex food protein hydrolysates and biological fluids has been made easier with the enhanced precision of liquid chromatography mass-spectrometry (LC-MS) analysers 25 . Furthermore, bioinformatic tools have allowed the establishment of structure-function relationships between BAPs and their in vitro bioactivity 26, 27 . In addition, 5 peptide alignment strategies have made it possible to discriminate peptide motifs which correlate with specific bioactive properties 28, 29 . Establishment of structure-function relationships has highlighted the importance of specific amino acid residues within BAPs. For example, Y, L, P and W residues appear to play a 10 specific role in opioid, antioxidant, insulinotropic, along with angiotensin converting enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory peptides 8, 28, 30, 31 . This review assesses the contribution of W and W-containing peptides to the bioactive properties of milk protein hydrolysates. The targeted release of 15 free W and W-containing peptides during the digestion of milk proteins will be outlined. Furthermore, the literature on the stability of W and W-containing peptides following different processing conditions, which are relevant to food manufacture, will be assessed. 
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Release of free W and W-containing peptides during the digestion of milk proteins
A limited number of studies have investigated the release of peptides from milk proteins during gastrointestinal (GI) digestion in humans [32] [33] [34] [35] [36] . Free W and/or W-containing peptides originating 30 from milk proteins may be released in the GIT following the digestion of milk proteins 32, 36, 37 . Furthermore, using in silico approaches, the release of free W and W-containing peptides by GI enzymes can be predicted (Table 2) . Chymotrypsin, in particular, is able to cleave milk proteins at the C-terminus of W 35 residues 38 . In silico digestion of the major milk proteins with GI enzymes has shown that free W may be released by chymotrypsin from α s1 -CN, α-La and bovine serum albumin (BSA). In addition, W-containing peptides with 2-71 amino acid residues may also be released from all major milk proteins (α s1 -, α s2 -, -and -CN, α- 40 La, -Lg, LF and BSA, Table 2 ).
However, to date, only a limited number of W-containing peptides have been identified in biological samples obtained from humans (Table 3) , including the jejunal contents 32 and the sera 24 . Peptide cutter programs generally only allow prediction of 45 peptides which may be released by one enzyme activity, while digestion in humans involves the hydrolytic activity of several enzymes (proteinases and peptidases). In general, the peptides which were predicted in silico to be released by GI enzymes (Table 2) have not been identified in the GIT (Table 3) . However, 50 larger β-CN peptides predicted to be released in silico (Table 2) may act as precursors of the five β-CN derived W-containing peptides which has been identified in the jejunal contents of humans 32 . These peptide precursors may be further cleaved by carboxy-and aminopeptidases present in the GIT of humans 39,40 . 55 In the late 1980's, contaminated batches of W supplements caused several cases of eosinophilia myalgia syndrome, which was fatal in certain instances. However, it has been demonstrated that W is a non-toxic amino acid 41 . Its median lethal dose (LD 50 ) was determined as being as high as 1.6 g kg -1 in rats 42 , 60 corresponding to ~ 1.4 g kg -1 in humans 6 . It is well accepted that free amino acids and peptides are more easily absorbed than unhydrolysed proteins 40, 43, 44 . W is found in the circulation mainly in a bound form with BSA 6 . However, W is thought to be able to cross the blood brain barrier (BBB) in a free form as it has 65 a higher affinity for BBB transporters than for BSA 5 . The transfer of W to the brain is thought to be reduced by the presence of large neutral amino acids (LNAA) which compete for the same transporter 6 . In this context, W supplements, which are more concentrated than dietary sources, allow for its increased 70 bioavailability in the brain 41 . However, because the incorporation of W into proteins depends on the presence of other amino acids, it has been suggested that intake of W from supplements causes an imbalance which may not be consistent with efficient protein synthesis. Therefore, intake of dietary W appears more efficient 75 for protein synthesis than W supplements 6 . Foltz, et al. 26 studied the intestinal stability of dipeptides in silico and in vitro. Most W-containing dipeptides found within the milk proteins which were evaluated, were not stable to in vitro intestinal digestion, with the exception of GW (LF (f124- 80 125) and LF (f466-467)). There are a limited number of reports of W-containing peptides being identified in the circulation of humans. LW, an ACE inhibitory peptide which is predicted to be released from  s1 -CN by pepsin ( antioxidant, antidiabetic and satiating agents will be outlined in the following sections. Intake of W has been linked with an increase in serotonin level in the brain of animal 45 and human subjects 41 . Increased serotonin levels in the central nervous system may beneficially 15 modulate stress-related and cognitive function 41, [46] [47] [48] [49] . A significant increase in plasma W:LNAA ratio was seen, which induced anxiolytic-like effects in rats fed with -La enriched whey proteins (190 g kg -1 ). The anxiolytic effects may be related to an increase in serotonin synthesis and release 45 . Consumption 20 of -La, a W rich protein, induced a 48% increase in plasma W:LNAA ratio compared to a CN diet 50 . This increase was thought to be followed by a higher serotonin concentration in the hypothalamus of human subjects 50, 51 . A positive effect on depressive mood and a better ability to cope with stress 25 (reduction of cortisol-related stress) was seen in stress-vulnerable human subjects 50 . Evening intake of α-La induced a relatively high increase in plasma W:LNAA ratio (+ 130%, 2 h after intake) followed by improved morning alertness (reduced sleepiness) and vigilance performance which were explained by a better sleep 30 quality 52 . Similarly in another study, free W intake was shown to improve cognitive function (significantly shorter reaction time in a memory scanning test) in highly stressed human subjects 51 . However, this positive effect was not seen in low stress vulnerable subjects. Increased serotonin level in highly stressed 35 subjects may have caused a reduction of stress levels which was followed by better cognitive performances 51 . Other studies have also reported an increase in the plasma W:LNAA ratio in healthy females following -La intake (40 g). However, this was not followed by beneficial modifications in subjective ratings of 40 mood or anxiety 53 . It has been proposed that the plasma W:LNAA ratio may be further increased by the intake of hydrolysed vs. intact -La 46 Several in silico approaches including quantitative structure activity relationship (QSAR) and molecular docking have been utilised in an attempt to predict the ACE inhibitory activity of peptides. These studies have allowed a better understanding of 15 the structural features of peptides displaying ACE inhibitory activity (Fig. 2) . These analyses indicated that the presence of branched chain amino acids (L and I) or C and G at the Nterminus and R, W, P, K, F or Y at the C terminus are associated with potent ACE inhibitory activity 24, 27, 30, 59 . -CN (f163-164) ), IW (α-La (f 59-60) and LF (f 267-268)) and VW (LF (f 346-347) and 50 LF (f 548-549)) were shown to be competitive inhibitors of human ACE 62, 63 . The -La-derived peptides, IW and WL (α-La (f 104-105) and α-La (f 118-119)) were identified in milk proteinbased infant formulae 64 and in a whey protein hydrolysate generated with a combination of chymotrypsin and thermolysin 55 62 . The yield for the release of IW was estimated between 4-19% in the infant formulae 64 and at 50% (w/w) in a whey protein hydrolysate 62 . While that of WL was 4% (w/w) in a whey protein hydrolysate 62 . Simulated gastrointestinal digestion (SGID) revealed that AW and IW, when present in an hydrolysate, were 60 stable to the hydrolytic action of pepsin but were significantly degraded (59 and 40% (w/w), respectively) on incubation with pancreatic enzyme activities 62 . Localisation of the W residue at the C-terminal position of dipeptides (RW and VW) has been correlated with higher ACE 65 inhibitory properties as compared to the reverse peptides (WR and WV). These differences were explained by the fact that higher hydrophobic interactions at the S2' hydrophobic sub-site of the C-domain of the ACE active site could take place when W was located at the C-terminal side of dipeptides 63 .
70
LW ( s1 -CN (f198-199)) and IW were administered to spontaneous hypertensive rats (SHR) at 10 and 60 mg kg -1 , by intravenous injection and oral administration, respectively 65 . LW caused a decrease in systolic blood pressure (SBP) of -45 and -22 mmHg after intravenous injection and oral administration, 75 respectively. While IW reduced SBP by -55 and -22 mmHg after intravenous injection and oral administration, respectively 65 .
Antioxidant activity of W and W-containing peptides
Free amino acids and milk protein-derived peptides may act as 80 antioxidant compounds. The mechanisms involved in the antioxidant activity comprise radical scavenging of oxidative species and the modulation of enzymes involved in the in vivo oxidative system 12 . Milk protein-derived peptides which are able to scavenge antioxidant species are generally short (< 11 amino 85 acid residues) peptides containing hydrophobic (P, H, Y and W) and/or sulphur (C and M) residues 9, 11, [66] [67] [68] [69] [70] [71] . A study on the antioxidant activity of 18 free amino acids (V, I, D, T, L, E, A, M, Y, H, F, W, C, N, K, G, Q and P) using the ORAC assay has shown that W displayed the highest activity 72 . Another study has 90 assessed the antioxidant activity of free amino acids using the 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) ABTS assay. Four amino acids displayed a scavenging activity of the ABTS radical in the following order C > W > Y > H 73 . Similarly, the importance of W has been demonstrated in the scavenging of 95 reactive oxygen and nitrogen species 3 as well as in the scavenging of peroxyl radical and the inhibition of linoleic acid autoxidation 74 . It has been suggested that phenol and indole amino acids within peptides may act as hydrogen donors, resulting in the formation of stable radicals and a reduction in the 100 rate of oxidation propagation 11, 69, 72 . The inhibition and activation of metabolic enzymes involved in the oxidative system have also been demonstrated in a few studies with W-containing peptides. The role of W in xanthine oxidase (XO) inhibition was hypothesised based on its structural similarities with its natural substrate, xanthine (Fig. 1) , and a drug 10 inhibitor of XO, Allopurinol 79 . This was confirmed by the fact that out of the 20 amino acids tested, W was the only one to display inhibitory properties against XO 80 . The inhibition of xanthine oxidase (XO) in vitro by free W, RW, IW, KW, WV and VW has been reported 79, 80 . Similarly, LF hydrolysates were also 15 able to inhibit XO. This was attributed to the W-containing peptides within the hydrolysates as shown following further enrichment of the hydrolysates using activated carbon 79 . Prooxidant activity of free W has been reported in Caco-2 cells 81 . Interestingly, an adaptive response through the nuclear factor 20 (erythroid-derived 2)-like 2 (Nrf-2) pathway was demonstrated, which resulted in an increase in glutathione peroxidase transcription level.
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A compendium of antioxidant activity of W and W-containing peptides, as determined by different assays, is presented in Table   25 5. Free W displays a lower anti-oxidant capacity than peptides, e.g., with 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging. However, in other instances, free W antioxidant activity was as high as that of W-containing peptides such as with the oxygen radical absorbance capacity (ORAC) assay and with XO 30 inhibition (Table 5 ). In addition, the peptide sequence also affected the antioxidant activity as demonstrated in studies conducted with reverse peptides 79, 82, 83 or when substituting amino acids in peptides 74 . It is interesting to note that certain peptides yielded good antioxidant properties across different 35 assays (Table 5 ). This was the case for WV and VW which were able to scavenge DPPH and superoxide (SO) radicals and inhibit XO; for WY which displayed ORAC activity and scavenged DPPH and for KW which scavenged DPPH and inhibited XO.
Antidiabetic potential of W and W-containing
peptides
The consumption of intact and hydrolysed milk proteins has been linked, in certain instances, with an increase in insulin secretion in the post-prandial phase. This insulinotropic effect may be followed by a reduction in serum glucose both in animal models 45 84-86 and in humans 16, 18, [87] [88] [89] [90] . The insulinotropic effect of milk proteins has been linked with an increase in plasma amino acid level, in particular branched chain amino acids (BCAA), following the consumption of milk proteins. A human study has reported on the insulinotropic and serum glucose lowering effect 50 of free W. It was shown that intravenous infusion of W (amount infused: 2.5-22.5 g) increased plasma insulin, displaying a similar potency as L 91 . However, the role of W in insulin secretion has not been extensively studied. This may arise from limitations in the analytical methodologies used to quantify free amino acids 55 which often lead to a heat-induced destruction of W, thus making it challenging to quantify 92 . However, different strategies for W residue protection during acid hydrolysis involving the utilisation of antioxidants (e.g. thioglycolic acid), reducing agents (e.g. pyridine borane) and organic acids (e.g. p-toluene sulfonic acid) 60 have been suggested. A lower level of W degradation is generally observed during alkaline hydrolysis in the absence of oxygen 93 .
ARTICLE TYPE www.rsc.org/xxxxxx | XXXXXXXX DPP-IV is a metabolic enzyme which is responsible for the cleavage and subsequent inactivation of the incretin hormones glucagon like peptide 1 (GLP-1) and glucose inhibitory 10 polypeptide (GIP) 98 . These incretins, which have been shown to have an insulinotropic activity during the post-prandial phase, contribute to the regulation of serum glucose levels in humans. Therefore, inhibition of DPP-IV is a strategy which is being employed, notably with pharmaceutical drugs (gliptins) to help in 15 the management of type 2 diabetes 99 . Several food protein hydrolysates have been shown to display DPP-IV inhibitory properties in vitro 100 . Out of the 20 conventional amino acids, it was shown that M, L and W were able to inhibit DPP-IV 80 . However, their IC 50 's were relatively high (> 2000 µM). In 20 certain instances specific peptide sequences have been linked with DPP-IV inhibition 94, [101] [102] [103] [104] [105] . Milk protein-derived DPP-IV inhibitory peptides generally have an IC 50 value in the µM range 28 , which is several orders of magnitude higher than that of gliptins (nM) 106 . To date, four in vivo studies have demonstrated 25 that food protein hydrolysates or peptides with in vitro DPP-IV inhibitory properties were able to induce an increased insulin secretion and a reduction in plasma glucose following an oral glucose tolerance test in rodents. This was the case with a tryptic digest of β-Lg administered (300 mg kg -1 body weight) to mice 30 107 , the peptide LPQNIPPL (β-CN (f70-77)) isolated from Goudatype cheese, administered (300 mg kg -1 body weight) to rats 108 and porcine and Atlantic salmon skin gelatin hydrolysates administered (300 mg day -1 for 42 days) to streptozotocininduced diabetic rats 109, 110 . The insulinotropic effects observed 35 were only directly linked with DPP-IV inhibition in vivo in two instances where plasma DPP-IV activity was shown to be reduced following the ingestion of a DPP-IV inhibitory porcine 110 or Atlantic salmon skin gelatin hydrolysate 109 . A limited number of potent DPP-IV inhibitory peptide 40 sequences have been identified to date. While several DPP-IV inhibitory peptides possess between 2-8 amino acids 111, 112 , longer peptide sequences with > 13 amino acid residues have also been identified 113 . DPP-IV IC 50 values of W and W-containing peptides inhibitors of DPP-IV are listed in An attempt to link in vitro DPP-IV inhibitory properties to the physicochemical characteristics (molecular mass, hydrophobicity hydrophobic moment (μH), isoelectric point (pI) and charge) of the peptides has been conducted 117 . However, no obvious 10 relationship between the physicochemical characteristics of the peptides and their bioactivity could be determined. In contrast, other specific features in DPP-IV inhibitory peptide sequences have been shown to correlate with their in vitro activity. It was reported that hydrophobic peptides with Xaa-Pro, Pro-Xaa or 15 Xaa-Ala (with Xaa, an amino acid residue) sequences may be relatively potent DPP-IV inhibitors 118 . Different structural features have been elucidated from relatively potent DPP-IV inhibitory peptides (with IC 50 values < 200 µM) using a peptide alignment approach. This analysis revealed that these peptides 20 generally contained a W at the N-terminus and/or a Pro at position 2 28 . These characteristic features of DPP-IV inhibitory peptides were further confirmed in a more recent study where a similar approach was taken 29 . Similarly, analysis of a dipeptide library revealed that the most potent DPP-IV inhibitory peptides 25 generally contained a W residue at the N-terminal position 114 . Interestingly, the specific location of W at the N-terminus of peptides is crucial for DPP-IV inhibitory activity. It was shown with dipeptide isomers that DPP-IV inhibitory activity was significantly reduced or lost when the W residue was located at 30 the C-terminal position of the peptide 83 . Several W-containing peptides were shown to be noncompetitive, linear mixed-or parabolic mixed-type inhibitors of DPP-IV 83, 94, 116, 119 . This suggests that these peptides do not directly bind to the active site of DPP-IV 94, 120 . Taking in silico 35 approaches, it was proposed that W-containing peptides were likely to bind to a secondary binding site located in the neighborhood of the active site of DPP-IV 80 . Certain Wcontaining peptides appear to act through different mechanisms which are still not fully understood and would merit more 40 investigation since these peptides appear to be relatively potent DPP-IV inhibitors.
Satiating properties of W and W-containing peptides
Consumption of milk proteins has been proposed as a means to 45 increase satiety in humans 87, [121] [122] [123] . The satiating effects of milk proteins are thought to involve the kinetics of amino acid appearance in the circulation and the rheological properties of the proteins in the GIT 124 . Satiating effects have particularly been observed with whey proteins [125] [126] [127] , which are digested faster than 50 CNs 40, 128 . In particular, when -La was administered at breakfast to adults, a subsequent 25% reduction in energy intake in an ad libitum lunch was seen 129 . No effect was seen with CN, whey, and whey with caseinomacropeptide (CMP) 129 .
A link between serotonin activation and milk protein intake 55 has been suggested. This has been explained by the fact that milk proteins are a source of W, the sole precursor of serotonin 130 . Consumption of -La has been shown to increase plasma W in rats 45 and in humans 50, 129 , which may result in higher hypothalamic serotonin concentrations 50 . Different milk protein 60 (whey and CN-derived) hydrolysates have been shown to act as serotonin 5-HT 2C receptor agonist in embryonic kidney cell lines (HEK 293A) 131, 132 . While no effect was seen in vivo with the 1 kDa permeate of a whey protein hydrolysate, the 1 kDa permeate of a CN hydrolysate was show to yield a significant reduction in 5 cumulative food intake when administered intraperiteonally (500 mg kg −1 body weight) to mice 131 .
Effect of processing conditions on W stability and bioactivity
The stability of W and W-bound peptides/proteins to different 10 processing conditions has been reviewed 92 . W is relatively stable to processing conditions (steam sterilisation, industrial and home cooking) in comparison to other amino acids such as K, M and C 92, 133 . However, the application of severe processing (heat in the presence of oxygen and sunlight exposure) applied to milk 15 proteins can lead to the degradation of W and subsequently to reduced bioavailability or the formation of antinutritional and toxic/carcinogenic (carboline and Maillard) compounds 92 . The reactivity (oxidation and substitution reactions) of W to different chemicals has been attributed to its indole structure. At 93 . Maillard reactions occur between primary amino (ϵ-or -NH 2 ) groups and reducing carbohydrates following heat treatment. The ϵ-NH 2 group from W has been shown to be able to participate in Maillard reactions 93 . In addition, W may be further degraded by oxidative species 30 which are generated during Maillard reactions 134 . The oxidative degradation of W via Maillard reaction products is also termed glycoxidation (glycation and oxidation). W glycoxidation only appears to occur in native -La. This may arise from the fact that W residues within heat-denatured -La are not easily accessible 35 to radicals due to the formation of -La aggregates 134 . Similarly, the effect of lipid-derived oxidative products on the reduced bioavailability of W (-27.9%) from whey proteins following storage at 37C for 4 weeks has been reported 133 . 
Conclusion
